Emerging biotechnological strategies for non-viral antiangiogenic gene therapy

Angiogenesis

Volumn 15, Issue 4, 2012, Pages 521-542

  Liu, Chunxi ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Antiangiogenic gene therapy; Biotechnological strategies; Non viral vectors; RNA interference; Tumor associated macrophages; Vascular endothelial growth factor

Indexed keywords

AGN 211745; BEVACIZUMAB; BORTEZOMIB; CALAA 01; CETUXIMAB; CYL 02; DASATINIB; EGEN 001 301; EGEN 001301; ERLOTINIB; EW A 401; EWA 401; GEFITINIB; GENE THERAPY AGENT; GL 67A; GM 169; INTERLEUKIN 1; INTERLEUKIN 12; LAPATINIB; NL 003; PANITUMUMAB; PEGAPTANIB; RANIBIZUMAB; RECOMBINANT ENDOSTATIN; SCIB 1; SORAFENIB; SUNITINIB; TD 101; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 165; VLTS 589; VM 202; XRP 0038; ZYC 300;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ARTERIOSCLEROSIS; BIOTECHNOLOGY; BREAST CANCER; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CONGENITAL PACHYONYCHIA; CRITICAL LIMB ISCHEMIA; CYSTIC FIBROSIS; ELECTROPORATION; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY CANCER; LARGE CELL NEUROENDOCRINE CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PERIPHERAL VASCULAR DISEASE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; RETINA MACULA DEGENERATION; REVIEW; RNA INTERFERENCE; SKIN CARCINOMA; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 84875052761     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9295-8     Document Type: Review

References (139)

1. Segal E, Satchi-Fainaro R (2009) Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 61(13):1159-1176. doi:10.1016/j.addr.2009.06.005.
2. Cao Y (2010) Angiogenesis: what can it offer for future medicine? Exp Cell Res 316(8):1304-1308. doi:10.1016/j.yexcr. 2010.02.031.
3. Oshima Y, Yajima S, Yamazaki K, Matsushita K, Tagawa M, Shimada H (2010) Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg 16(6):389-393.
4. Oba M, Vachutinsky Y, Miyata K, Kano MR, Ikeda S, Nishiyama N, Itaka K, Miyazono K, Koyama H, Kataoka K (2010) Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble flt-1. Mol Pharm 7(2):501-509. doi:10.1021/mp9002317.
5. Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, Feder B, Waitsman A, Barshack I, Goldberg I, Mazaki-Tovi S, Peled M, Harats D (2009) Systemic administration of radiation- potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Cancer Biol Ther 8(5):424-432.
6. Wyder L, Suply T, Ricoux B, Billy E, Schnell C, Baumgarten BU, Maira SM, Koelbing C, Ferretti M, Kinzel B, Muller M, Seuwen K, Ludwig MG (2011) Reduced pathological angiogenesis and tumor growth in mice lacking GPR4, a proton sensing receptor. Angiogenesis 14(4):533-544. doi:10.1007/s10456-011-9238-9.
7. Mitsos S, Katsanos K, Koletsis E, Kagadis GC, Anastasiou N, Diamantopoulos A, Karnabatidis D, Dougenis D (2012) Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis 15(1):1-22. doi:10.1007/s10456-011-9240-2.
8. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320(2):130-137. doi:10.1016/j.canlet.2012. 03.008.
9. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7(6):383-388. doi:10.1038/nnano.2012.45.
10. Ingold B, Simon E, Ungethum U, Kuban RJ, Muller BM, Lupp A, Neumann U, Ebert MP, Denkert C, Weichert W, Schulz S, Rocken C (2010) Vascular CXCR4 expression-a novel antiangiogenic target in gastric cancer? PLoS ONE 5(4):e10087. doi:10.1371/journal.pone.0010087.
11. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103(27):10391-10396. doi:10.1073/pnas. 0600937103. (Pubitemid 44051177)
12. Berger M, Bergers G, Arnold B, Hammerling GJ, Ganss R (2005) Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 105(3):1094-1101. doi:10.1182/blood-2004-06-2315. (Pubitemid 40170880)
13. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Grone HJ, Hammerling GJ, Arnold B, Ganss R (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453(7193): 410-414. doi:10.1038/nature06868. (Pubitemid 351693122)
14. Ziche M, Donnini S, Morbidelli L (2004) Development of new drugs in angiogenesis. Curr Drug Targets 5(5):485-493. (Pubitemid 38807822)
15. Stahl A, Joyal JS, Chen J, Sapieha P, Juan AM, Hatton CJ, Pei DT, Hurst CG, Seaward MR, Krah NM, Dennison RJ, Greene ER, Boscolo E, Panigrahy D, Smith LE (2012) SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood. doi: 10.1182/blood-2012-04-422527.
16. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579-591. doi:10.1038/nrc2403.
17. Taraboletti G, Rusnati M, Ragona L, Colombo G (2010) Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 1(7):662-673.
18. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
19. Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, Fasol U, Buchert M, Kratzschmer J, Delesen H, Rajagopalan P, Christensen O (2011) Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. Vasc Cell 3:16. doi:10.1186/2045-824X-3-16.
20. Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG (2011) Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol 179(5):2589-2600. doi:10.1016/j.ajpath.2011.07.035.
21. Kunnakkat S, Narayana A(2011) Bevacizumab in the treatment of high-grade gliomas: an overview. Angiogenesis 14(4):423-430. doi:10.1007/s10456-011-9232-2.
22. Ghaedi M, Soleimani M, Taghvaie NM, Sheikhfatollahi M, Azadmanesh K, Lotfi AS, Wu J (2011) Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. J Gene Med 13(3):171-180. doi:10.1002/jgm.1552.
23. Cressman S, Dobson I, Lee JB, Tam YY, Cullis PR (2009) Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. Bioconjug Chem 20(7):1404-1411. doi:10.1021/bc900041f.
24. Kim SW, Kim WJ, Yockman JW, Lee M, Jeong JH, Kim YH (2005) Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 106(1-2):224-234. doi:10.1016/j.jconrel.2005.04.016. (Pubitemid 41140097)
25. Brock CS, Lee SM (2002) Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 19(3):557-570. (Pubitemid 34256975)
26. Brandwijk RJ, Griffioen AW, Thijssen VL (2007) Targeted gene-delivery strategies for angiostatic cancer treatment. Trends Mol Med 13(5):200-209. doi:10.1016/j.molmed.2007.03.001. (Pubitemid 46705505)
27. Quesada AR, Munoz-Chapuli R, Medina MA (2006) Antiangiogenic drugs: from bench to clinical trials. Med Res Rev 26(4):483-530. doi:10.1002/med.20059. (Pubitemid 43939203)
28. Kleinman HK, Liau G (2001) Gene therapy for antiangiogenesis. J Natl Cancer Inst 93(13):965-967. (Pubitemid 32677389)
29. Tebes SJ, Kruk PA (2005) The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer. Gynecol Oncol 99(3):736-741. doi:10.1016/j.ygyno. 2005.08.031. (Pubitemid 41686561)
30. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG (2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 129(2):107-116. doi:10.1016/j.jconrel. 2008.03.008.
31. Green JJ, Chiu E, Leshchiner ES, Shi J, Langer R, Anderson DG (2007) Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett 7(4):874-879. doi:10.1021/nl062395b. (Pubitemid 46717725)
32. Green JJ, Langer R, Anderson DG (2008) A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res 41(6):749-759. doi:10.1021/ar7002336.
33. Conley SM, Naash MI (2010) Nanoparticles for retinal gene therapy. Prog Retin Eye Res 29(5):376-397. doi:10.1016/j.preteyeres.2010.04.004.
34. Makarevich P, Tsokolaeva Z, Shevelev A, Rybalkin I, Shevchenko E, Beloglazova I, Vlasik T, Tkachuk V, Parfyonova Y (2012) Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS ONE 7(6):e38776. doi:10.1371/journal.pone.0038776.
35. Andrieu-Soler C, Doat M, Halhal M, Keller N, Jonet L, BenEzra D, Behar-Cohen F (2006) Enhanced oligonucleotide delivery to mouse retinal cells using iontophoresis. Mol Vis 12:1098-1107. (Pubitemid 44473664)
36. Niidome T, Huang L (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9(24):1647-1652. doi: 10.1038/sj.gt.3301923. (Pubitemid 36104607)
37. Heller LC, Heller R (2006) In vivo electroporation for gene therapy. Hum Gene Ther 17(9):890-897. doi:10.1089/hum. 2006.17.890. (Pubitemid 46076749)
38. Murakami T, Sunada Y (2011) Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 11(6):447-456.
39. Li Y, Wang J, Satterle A, Liu F (2012) Gene transfer to skeletal muscle by site-specific delivery of electroporation and ultrasound. Biochem Biophys Res Commun. doi:10.1016/j.bbrc. 2012.06.090.
40. Cai X, Conley SM, Nash Z, Fliesler SJ, Cooper MJ, Naash MI (2010) Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 24(4):1178-1191. doi:10.1096/fj.09-139147.
41. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI (2009) A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS ONE 4(4):e5290. doi:10.1371/journal.pone. 0005290.
42. Akin D, Sturgis J, Ragheb K, Sherman D, Burkholder K, Robinson JP, Bhunia AK, Mohammed S, Bashir R (2007) Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat Nanotechnol 2(7):441-449. doi:10.1038/nnano.2007.149. (Pubitemid 47035615)
43. Gardlik R, Behuliak M, Palffy R, Celec P, Li CJ (2011) Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther 18(5):425-431. doi:10.1038/gt.2010.176.
44. Seow Y, Wood MJ (2009) Biological gene delivery vehicles: beyond viral vectors. Mol Ther 17(5):767-777. doi:10.1038/mt. 2009.41.
45. van Pijkeren JP, Morrissey D, Monk IR, Cronin M, Rajendran S, O'Sullivan GC, Gahan CG, Tangney M (2010) A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther 21(4):405-416. doi:10.1089/hum. 2009.022.
46. Schoen C, Loeffler DI, Frentzen A, Pilgrim S, Goebel W, Stritzker J (2008) Listeria monocytogenes as novel carrier system for the development of live vaccines. Int J Med Microbiol 298(1-2):45-58. doi:10.1016/j.ijmm.2007.09. 002. (Pubitemid 350216561)
47. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA (2004) Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22(3): 313-320. doi:10.1038/nbt937. (Pubitemid 38295764)
48. Gardlik R, Hodosy J, Palffy R, Behuliak M, Janega P, Celec P (2010) Effects of orally administered bacteria carrying HIF- 1alpha gene in an experimental model of intestinal ischemia. Arch Med Res 41(5):332-337. doi:10.1016/j.arcmed.2010.07. 009.
49. Palffy R, Gardlik R, Hodosy J, Behuliak M, Resko P, Radvansky J, Celec P (2006) Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 13(2):101-105. doi:10.1038/sj.gt.3302635. (Pubitemid 43039902)
50. Cao S, Cripps A, Wei MQ (2010) New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol 37(1):108-114. doi:10.1111/j.1440-1681.2009.05268.x.
51. Schoen C, Kolb-Maurer A, Geginat G, Loffler D, Bergmann B, Stritzker J, Szalay AA, Pilgrim S, Goebel W (2005) Bacterial delivery of functional messenger RNA to mammalian cells. Cell Microbiol 7(5):709-724. doi:10.1111/j.1462-5822. 2005.00507.x. (Pubitemid 40585012)
52. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, Chan M, Li H, Yew NS, Cheng SH, Boyd AC, Davies JC, Griesenbach U, Porteous DJ, Sheppard DN, Munkonge FM, Alton EW, Gill DR (2008) CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26(5):549-551. doi:10.1038/nbt1399. (Pubitemid 351668040)
53. Loessner H, Weiss S (2004) Bacteria-mediated DNA transfer in gene therapy and vaccination. Expert Opin Biol Ther 4(2): 157-168. doi:10.1517/14712598.4.2. 157. (Pubitemid 38200429)
54. Celec P, Gardlik R, Palffy R, Hodosy J, Stuchlik S, Drahovska H, Stuchlikova M, Minarik G, Lukacs J, Jurkovicova I, Hulin I, Turna J, Jakubovsky J, Kopani M, Danisovic L, Jandzik D, Kudela M, Yonemitsu Y (2005) The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor-an alternative gene therapy. Med Hypotheses 64(3):505-511. doi: 10.1016/j.mehy.2004.07.039. (Pubitemid 40023010)
55. Park HJ, Yang F, Cho SW (2012) Nonviral delivery of genetic medicine for therapeutic angiogenesis. Adv Drug Deliv Rev 64(1):40-52. doi:10.1016/j.addr. 2011.09.005.
56. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M (2003) Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105(4):561-567. doi:10.1002/ijc.11108. (Pubitemid 36578564)
57. Zhao W, Zhuang S, Qi XR (2011) Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine 6:3087-3098. doi:10.2147/IJN. S25399.
58. Kuesters GM, Campbell RB (2010) Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine (Lond) 5(2):181-192. doi:10.2217/nnm.09.105.
59. Chen SH, Zhaori G (2011) Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest 41(2):221-232. doi:10.1111/j.1365-2362.2010.02400.x.
60. Spagnou S, Miller AD, Keller M (2004) Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43(42):13348-13356. doi:10.1021/bi048950a. (Pubitemid 39391135)
61. Gary DJ, Puri N, Won YY (2007) Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 121(1-2):64-73. doi:10.1016/j.jconrel.2007.05.021. (Pubitemid 47126065)
62. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT (2012) Selfassembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 11(4):316-322. doi:10.1038/nmat3253.
63. Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, Ishida T, Kiwada H (2012) Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm 422(1-2):280-289. doi:10.1016/j.ijpharm.2011.10.059.
64. Ko YT, Falcao C, Torchilin VP (2009) Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 6(3):971-977. doi:10.1021/mp900006h.
65. Ming X, Sato K, Juliano RL (2011) Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release 153(1):83-92. doi:10.1016/j.jconrel.2011.04.029.
66. Popplewell LJ, Abu-Dayya A, Khana T, Flinterman M, Abdul Khalique N, Raju L, Opstad CL, Sliwka HR, Partali V, Dickson G, Pungente MD (2012) Novel cationic carotenoid lipids as delivery vectors of antisense oligonucleotides for exon skipping in Duchenne muscular dystrophy. Molecules 17(2):1138-1148. doi:10.3390/molecules17021138.
67. Hagigit T, Abdulrazik M, Valamanesh F, Behar-Cohen F, Benita S (2011) Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: an in vivo study in rats and mice. J Control Release. doi: 10.1016/j.jconrel.2011.11.022.
68. Bruxel F, Cojean S, Bochot A, Teixeira H, Bories C, Loiseau PM, Fattal E (2011) Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. Int J Pharm 416(2):402-409. doi:10.1016/j.ijpharm. 2011.01.048.
69. Peddada LY, Harris NK, Devore DI, Roth CM (2009) Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum. J Control Release 140(2): 134-140. doi:10.1016/j.jconrel.2009.08.008.
70. Kuramoto Y, Nishikawa M, Hyoudou K, Yamashita F, Hashida M (2006) Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release 115(2):226-233. doi: 10.1016/j.jconrel.2006.08.002. (Pubitemid 44537504)
71. Sun T, Zhang Z, Cao X, Zhang M, Zhao X, Zhang Q, Chen M (2011) Antisense oligodeoxynucleotide complexation with phosphoryl-choline diblock copolymers and its effect on cell transfection. J Control Release 152(SUPPL. 1):e172-e173. doi: 10.1016/j.jconrel.2011.08.070.
72. Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N (2008) T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 68(13):1430-1442. doi:10.1002/pros.20807.
73. Gu SZ, Zhao XH, Zhang LX, Li L, Wang ZY, Meng M, An GL (2009) Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro. J Zhejiang Univ Sci B 10(3):159-167. doi:10.1631/jzus.B0820175.
74. Tandle A, Blazer DG III, Libutti SK (2004) Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2(1): 22. doi:10.1186/1479-5876-2-22. (Pubitemid 39130350)
75. Liu CC, Shen Z, Kung HF, Lin MC (2006) Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol 12(43):6941-6948. (Pubitemid 44834883)
76. Gardlik R, Celec P, Bernadic M (2011) Targeting angiogenesis for cancer (gene) therapy. Bratisl Lek Listy 112(8):428-434.
77. Sangro B, Qian C, Schmitz V, Prieto J (2002) Gene therapy of hepatocellular carcinoma and gastrointestinal tumors. Ann NY Acad Sci 963:6-12. (Pubitemid 34721690)
78. Dickerson EB, Akhtar N, Steinberg H, Wang ZY, Lindstrom MJ, Padilla ML, Auerbach R, Helfand SC (2004) Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2(12):663-673.
79. Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S, Baradaran B, Jalali MB, Dobakhti F, Lotfipour F (2011) Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J Pharm Pharm Sci 14(2):181-195.
80. Charoensit P, Kawakami S, Higuchi Y, Yamashita F, Hashida M (2010) Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther 17(7):512-522. doi: 10.1038/cgt.2010.12.
81. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17(3):360-369. doi:10.1038/gt.2009.159.
82. Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH, Anwer K (2009) Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med 11(8):718-728. doi:10.1002/jgm.1356.
83. Yang F, Jin C, Jiang YJ, Li J, Di Y, Fu DL (2011) Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert Rev Anticancer Ther 11(4):541-549. doi:10.1586/era.10.171.
84. Zhu H, Li Z, Mao S, Ma B, Zhou S, Deng L, Liu T, Cui D, Zhao Y, He J, Yi C, Huang Y (2011) Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther 18(12):884-896. doi: 10.1038/cgt.2011.57.
85. Kim WJ, Yockman JW, Jeong JH, Christensen LV, Lee M, Kim YH, Kim SW (2006) Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release 114(3): 381-388. doi:10.1016/j.jconrel.2006.05.029. (Pubitemid 44310812)
86. Kommareddy S, Amiji M (2007) Antiangiogenic gene therapy with systemically administered sFlt-1 plasmidDNAin engineered gelatin-based nanovectors. Cancer Gene Ther 14(5):488-498. doi:10.1038/sj.cgt.7701041. (Pubitemid 46588197)
87. Anguissola S, McCormack WJ, Morrin MA, Higgins WJ, Fox DM, Worrall DM (2011) Pigment epithelium-derived factor (PEDF) interacts with transportin SR2, and active nuclear import is facilitated by a novel nuclear localization motif. PLoS ONE 6(10):e26234. doi:10.1371/journal.pone.0026234.
88. Ek ET, Dass CR, Choong PF (2006) Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther 5(7):1641-1646. doi:10.1158/1535- 7163.MCT-06-0107. (Pubitemid 44323231)
89. Dass CR, Contreras KG, Dunstan DE, Choong PF (2007) Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 28(19):3026-3033. doi:10.1016/j.biomate rials.2007.03.016. (Pubitemid 46560874)
90. Cui FY, Song XR, Li ZY, Li SZ, Mu B, Mao YQ, Wei YQ, Yang L (2010) The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma. Oncol Rep 24(3):661-668.
91. Zhao MD, Sun YM, Fu GF, Du YZ, Chen FY, Yuan H, Zheng CH, Zhang XM, Hu FQ (2012) Gene therapy of endometriosis introduced by polymeric micelles with glycolipid-like structure. Biomaterials 33(2):634-643. doi:10.1016/j. biomaterials.2011. 09.077.
92. Deshayes S, Maurizot V, Clochard MC, Baudin C, Berthelot T, Esnouf S, Lairez D, Moenner M, Deleris G (2011) "Click" conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis. Pharm Res 28(7):1631-1642. doi:10.1007/s11095-011-0398-5.
93. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8(8):831-840. doi:10.1038/nm731.
94. Oh EJ, Choi JS, Kim H, Joo CK, Hahn SK (2011) Anti-Flt1 peptide-hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials 32(11):3115-3123. doi:10.1016/j. biomaterials.2011.01.003.
95. Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16(3):80-88. doi:10.1016/j.tcm.2006.01.003.
96. Temming K, Schiffelers RM, Molema G, Kok RJ (2005) RGDbased strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 8(6):381-402. doi:10.1016/j.drup.2005.10.002. (Pubitemid 43358061)
97. Salehi-Had H, Roh MI, Giani A, Hisatomi T, Nakao S, Kim IK, Gragoudas ES, Vavvas D, Guccione S, Miller JW (2011) Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization. PLoS ONE 6(4):e18864. doi:10.1371/journal.pone.0018864.
98. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60(3):722-727. (Pubitemid 30094573)
99. Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer 120(10):2243-2250. doi:10.1002/ijc.22528. (Pubitemid 46555865)
100. Chen Y, Wu JJ, Huang L (2010) Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18(4):828-834. doi:10.1038/mt.2009.291.
101. Liu C, Yu W, Chen Z, Zhang J, Zhang N (2011) Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene glycol) nanoparticles through caveolae-mediated endocytosis. J Control Release 151(2):162-175. doi:10.1016/j.jconrel.2011.02. 027.
102. Delli Carpini J, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13(1):43-58. doi:10.1007/s10456-010- 9163-3.
103. Ambasta RK, Sharma A, Kumar P (2011) Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell 3:26. doi:10.1186/2045-824X-3-26.
104. Cao Y (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2(59):re1. doi:10.1126/scisig nal.259re1.
105. Ferrara N (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20(4):158-163. doi:10.1684/ecn. 2009.0170.
106. Damasceno M (2011) Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Curr Opin Oncol 23(SUPPL.):S3-S9. doi:10.1097/01.cco.0000397417.75245.9c.
107. Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA 3rd, Hainsworth JD (2011) Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2 ? breast cancer. Clin Breast Cancer 11(5):297-305. doi:10.1016/j.clbc.2011.04.002.
108. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A (2003) Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 27(3):229-238. (Pubitemid 36708586)
109. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676. doi:10.1038/nm0603- 669. (Pubitemid 36749215)
110. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. doi:10.1007/s10456-011-9249-6.
111. Kim J, Kim SW, Kim WJ (2011) PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an antiangiogenic tumor therapeutic strategy. Oligonucleotides 21(2):101-107. doi:10.1089/oli.2011.0278.
112. Kowanetz M, Ferrara N (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12(17):5018-5022. doi:10.1158/1078-0432.CCR-06-1520. (Pubitemid 44453326)
113. Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80(4):705-713. doi:10.1189/jlb. 1105656. (Pubitemid 44835885)
114. Miselis NR, Wu ZJ, Van Rooijen N, Kane AB (2008) Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7(4):788-799. doi:10.1158/1535-7163.MCT-07-0579. (Pubitemid 351551032)
115. Polverini PJ, Cotran PS, Gimbrone MA Jr, Unanue ER (1977) Activated macrophages induce vascular proliferation. Nature 269(5631):804-806. (Pubitemid 8208827)
116. Wang B, Li Q, Qin L, Zhao S, Wang J, Chen X (2011) Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol 12:43. doi:10.1186/1471-2172-12-43.
117. Lee CC, Liu KJ, Wu YC, Lin SJ, Chang CC, Huang TS (2011) Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells. Inflammation 34(3):209-221. doi:10.1007/s10753-010-9226-z.
118. Melancon MP, Lu W, Huang Q, Thapa P, Zhou D, Ng C, Li C (2010) Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813. Biomaterials 31(25):6567-6573. doi:10.1016/j.biomaterials.2010. 05.001.
119. Banciu M, Schiffelers RM, Storm G (2008) Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. Pharm Res 25(8):1948-1955. doi:10.1007/s11095-008-9629-9.
120. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, Pasqualini F, Nebuloni M, Chiabrando C, Mantovani A, Allavena P (2010) Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 185(1):642-652. doi: 10.4049/jimmunol.1000413.
121. Li P, Liu D, Sun X, Liu C, Liu Y, Zhang N (2011) A novel cationic liposome formulation for efficient gene delivery via a pulmonary route. Nanotechnology 22(24):245104. doi:10.1088/0957-4484/22/24/245104.
122. Yu W, Liu C, Liu Y, Zhang N, Xu W (2010) Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res 27(8):1584-1596. doi:10.1007/s11095- 010-0149-z.
123. Huang Z, Zhang Z, Jiang Y, Zhang D, Chen J, Dong L, Zhang J (2012) Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release 158(2):286-292. doi:10.1016/j.jconrel. 2011.11.013.
124. Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A (2011) Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer. doi:10.1016/j.clcc.2011.05.006.
125. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286-4293. doi:10.1200/JCO.2010.34.1255.
126. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968-3976. doi:10.1200/JCO.2011.36.2236.
127. Cohn AL, Shumaker GC, Khandelwal P, Smith DA, Neubauer MA, Mehta N, Richards D, Watkins DL, Zhang K, Yassine MR (2011) An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 10(3):171-177. doi: 10.1016/j.clcc.2011.03.022.
128. Patel RD, Momi RS, Hariprasad SM (2011) Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol 26(6):372-379. doi:10.3109/08820 538.2011.570845.
129. Campa C, Harding SP (2011) Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12(2):173-181.
130. Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE (2010) Compounds in clinical Phase III and beyond. Recent Results Cancer Res 180:137-163. doi:10.1007/978-3- 540-78281-0-9.
131. Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, Cheung TT, Chan AC, Pang RW, Poon R, Fan ST, Yau T (2011) The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist 16(12):1721-1728. doi:10.1634/theoncologist.2011- 0192.
132. Procopio G (2011) Role of sorafenib in renal cell carcinoma: focus on elderly patients. Expert Rev Anticancer Ther 11(11): 1689-1692. doi:10.1586/era.11.153.
133. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous oncedaily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118(5):1252-1259. doi: 10.1002/cncr.26440.
134. Koh Y, Lee HE, Im SA, Kim SH, Kim TM, Han SW, Oh DY, Kim JH, Lee SH, Kim DW, Kim TY, Kim WH, Heo DS, Bang YJ (2011) VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagn Mol Pathol 20(3):143-147. doi:10.1097/PDM.0b013e3182107ea0.
135. Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ (2012) Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 18(3):486-492. doi:10.1016/j.bbmt.2011.12.580.
136. Cornelison AM, Welch MA, Koller C, Jabbour E (2011) Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation. Clin Lymphoma Myeloma Leuk 11(SUPPL. 1):S111- S113. doi:10.1016/j.clml.2011.03.032.
137. Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118(25):6521-6528. doi:10.1182/blood- 2011-05-351403.
138. Rugo HS, Jo Chien A, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN (2011) A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549- 011-1918-z.
139. Gabr AG, Goto H, Hanibuchi M, Ogawa H, Kuramoto T, Suzuki M, Saijo A, Kakiuchi S, Trung VT, Sakaguchi S, Moriya Y, Sone S, Nishioka Y (2012) Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis 29(3):207-216. doi:10.1007/s10585-011-9443-3.